Shares of Eli Lilly LLY decreased 0.3% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 58.96% year over year to $2.75, which beat the estimate of $2.35.
Revenue of $7,440,000,000 higher by 21.69% from the same period last year, which beat the estimate of $7,290,000,000.
Guidance
The upcoming fiscal year's EPS expected to be between $7.75 and $8.40.
The upcoming fiscal year's revenue expected to be between $26,500,000,000 and $28,000,000,000.
Conference Call Details
Date: Jan 29, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/ku6m85kq
Technicals
52-week high: $213.23
Company's 52-week low was at $117.06
Price action over last quarter: Up 59.55%
Company Profile
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.